Citigroup Initiates Coverage on LENZ Therapeutics (NASDAQ:LENZ)
Citigroup assumed coverage on shares of LENZ Therapeutics (NASDAQ:LENZ – Free Report) in a report issued on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $34.00 target price on the stock. Separately, Piper Sandler initiated coverage on LENZ Therapeutics in a report on Wednesday, March 27th. They issued an overweight rating and […]
14 Apr 08:30 · The Markets Daily